Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Moen EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, Topol EJ. Moen EK, et al. Among authors: miller dp. J Womens Health. 1997 Jun;6(3):285-93. doi: 10.1089/jwh.1997.6.285. J Womens Health. 1997. PMID: 9201663 Clinical Trial.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Mak KH, et al. Among authors: miller dp. J Am Coll Cardiol. 1997 Jul;30(1):171-9. doi: 10.1016/s0735-1097(97)00118-6. J Am Coll Cardiol. 1997. PMID: 9207639 Free article. Clinical Trial.
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators.
Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, Granger CB, Ross AM, Califf RM, Topol EJ. Migrino RQ, et al. Among authors: miller dp. Circulation. 1997 Jul 1;96(1):116-21. doi: 10.1161/01.cir.96.1.116. Circulation. 1997. PMID: 9236425 Clinical Trial.
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB, Miller DP, Underwood DA, Wagner GS. Sgarbossa EB, et al. Among authors: miller dp. J Am Coll Cardiol. 1998 Jan;31(1):105-10. doi: 10.1016/s0735-1097(97)00446-4. J Am Coll Cardiol. 1998. PMID: 9426026 Free article.
The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Narins CR, Miller DP, Califf RM, Topol EJ. Narins CR, et al. Among authors: miller dp. J Am Coll Cardiol. 1999 Mar;33(3):647-53. doi: 10.1016/s0735-1097(98)00620-2. J Am Coll Cardiol. 1999. PMID: 10080464 Free article. Clinical Trial.
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ. Pilote L, et al. Among authors: miller dp. N Engl J Med. 1995 Aug 31;333(9):565-72. doi: 10.1056/NEJM199508313330907. N Engl J Med. 1995. PMID: 7623907 Free article.
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ. Ellis SG, et al. J Am Coll Cardiol. 1998 Nov 15;32(6):1619-23. doi: 10.1016/s0735-1097(98)00403-3. J Am Coll Cardiol. 1998. PMID: 9822087 Free article. Clinical Trial.
374 results